In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Intarcia brings in $210mm via late-stage round of equity and debt

Executive Summary

In one of the largest private biotech financings over the past 25 years, Intarcia Therapeutics Inc. has raised a total of $210mm in a late-stage round. It sold $160mm in Series CC equity to new investors Baupost Group, Fidelity Investments, and two undisclosed institutions, and returning VCs including New Enterprise Associates, New Leaf Venture Partners, and Venrock Associates. Intarcia also sold $50mm in debt to Farallon Capital Management and an undisclosed institutional investor. The company will use the funds for Phase III trials--starting in early 2013--of its Type II diabetes drug ITCA650 in which the company plans to demonstrate that the compound is superior to other exenatide therapies and Merck's Januvia.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies